The COMBAT PRS system has already reported successful efficacy and tolerability outcomes. Further results will be presented during 2018.

References and Publications

1. Sánchez-García, S., Villarejo-Campos, P., Padilla-Valverde, D., Amo-Salas, M. & Martín-Fernández, J. Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study. Int. J. Hyperth. 32, 488–495(2016).
2. Sánchez-García, S., Padilla-Valverde, D., Villarejo-Campos, P., García-Santos, E. P. & Martín-Fernández, J. Hyperthermic chemotherapy intra-abdominal laparoscopic approach: development of a laparoscopic model using CO2 recirculation system and clinical translation in peritoneal carcinomatosis. Int. J. Hyperth. 33, 684–689 (2017).
3. Sánchez-García, S. et al. Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system. Surg. (United States) 155, 719–725 (2014).
4. Sánchez-García, S., Villarejo-Campos, P., Padilla-Valverde, D., et al. Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel in Advanced Ovarian Cancer. Preliminary results of clinical trial 10-008, EudraCT 2011-006319-69, NCT02681432. Presented Oral Communication. Congreso SEOQ y Reunión GECOP, Palma de Mallorca, España, 8-10 noviembre 2017.